PROCAPS GROUP SA (PROC) Stock Price, Quote, News and Overview
NASDAQ:PROC - Nasdaq - LU2376511205 - Common Stock - Currency: USD
PROC Quote, Performance and Key Statistics
PROCAPS GROUP SA
NASDAQ:PROC (2/3/2025, 5:09:31 PM)
After market: 0.9501 -0.06 (-5.93%)1.01
-0.58 (-36.51%)
The current stock price of PROC is 1.01 USD. In the past month the price decreased by -56.65%. In the past year, price decreased by -68.92%.
PROC Latest News, Press Releases and Analysis
Keep an eye on the top gainers and losers in Monday's session.
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Traders are paying attention to the gapping stocks in Monday's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Procaps Group Receives Delisting Notice From Nasdaq
Procaps Group Receives Delisting Notice From Nasdaq
MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated...
Procaps Group Receives Additional Delinquency Letter
Procaps Group Receives Additional Delinquency Letter
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated...
PROC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 79.69 | 769.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.83 | 366.98B | ||
| JNJ | JOHNSON & JOHNSON | 15.2 | 365.65B | ||
| MRK | MERCK & CO. INC. | 16.77 | 252.43B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.34 | 216.64B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 210.88B | ||
| PFE | PFIZER INC | 10.16 | 148.48B | ||
| SNY | SANOFI-ADR | 14.62 | 133.76B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.24 | 121.59B | ||
| ZTS | ZOETIS INC | 29.85 | 77.57B | ||
| GSK | GSK PLC-SPON ADR | 8.41 | 71.21B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 22.08 | 42.01B |
Related stock screener links
About PROC
Company Profile
Procaps Group SA is an international healthcare and pharmaceutical company. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
Company Info
PROCAPS GROUP SA
9, rue de Bitbourg
Luxembourg LU
CEO: Kyle P. Bransfield
Employees: 5500
Company Website: https://www.procapsgroup.com/
Investor Relations: https://investor.procapsgroup.com/
PROC FAQ
What is the stock price of PROC?
The current stock price of PROC is 1.01 USD.
What is the symbol for PROCAPS GROUP SA stock?
The exchange symbol of PROCAPS GROUP SA is PROC and it is listed on the Nasdaq exchange.
On which exchange is PROC stock listed?
PROC stock is listed on the Nasdaq exchange.
Is PROC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PROC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PROC.
Does PROC stock pay dividends?
PROC does not pay a dividend.
What is the Short Interest ratio of PROC stock?
The outstanding short interest for PROC is 0.7% of its float.
PROC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PROC. When comparing the yearly performance of all stocks, PROC is a bad performer in the overall market: 96.05% of all stocks are doing better.
PROC Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PROC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PROC. The Buy consensus is the average rating of analysts ratings from 8 analysts.